In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis

B. Benedetti, M. Rovaris, M. A. Rocca, D. Caputo, M. Zaffaroni, R. Capra, A. Bertolotto, V. Martinelli, G. Comi, Massimo Filippi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: The term benign multiple sclerosis (BMS) is referred to patients who have a mild or absent disability several years after disease clinical onset. Axonal damage can be measured in vivo using proton MR spectroscopy (1H-MRS). In this study, we quantified the severity of "global" axonal damage in BMS and early relapsing-remitting (RR) MS patients, using whole brain N-acetylaspartate (WBNAA) 1H-MRS, to better elucidate the structural correlates of a non-disabling disease evolution. Methods: WBNAA concentration was measured in 37 patients with BMS (mean disease duration 22.3 years) and 17 patients with early RRMS (mean disease duration 4.0 years), using an unlocalized 1H-MRS sequence. Dual echo and T1-weighted scans were also obtained to measure T2-hyperintense lesion volume (TLV) and normalized brain volume (NBV). Results: TLV was higher in BMS (mean TLV = 13.1 mL) than in early RRMS patients (mean TLV = 7.2 mL) (P = 0.018), whereas neither NBV (mean NBV: 1491.0 mL in BMS vs 1520.3 mL in RRMS) nor WBNAA concentration (mean WBNAA: 10.5 mmol in BMS vs 11.4 mmol in RRMS) significantly differed between the two groups. In MS patients, no correlation was found between WBNAA concentration and Expanded Disability Status Scale (EDSS), TLV and NBV. Conclusions: The similar WBNAA concentrations seen in BMS and early RRMS patients fit with the notion that a non-disabling long-term evolution of MS may be due, at least in part, to non-progression of pathology. Such a condition seems to be independent from MRI-visible lesions burden.

Original languageEnglish
Pages (from-to)789-794
Number of pages6
JournalMultiple Sclerosis Journal
Volume15
Issue number7
DOIs
Publication statusPublished - 2009

Fingerprint

Multiple Sclerosis
Brain
Matrix Attachment Regions
Relapsing-Remitting Multiple Sclerosis
N-acetylaspartate
Protons
Magnetic Resonance Spectroscopy
Pathology

Keywords

  • Axonal damage
  • Benign
  • MR spectroscopy
  • Multiple sclerosis
  • Relapsing-remitting

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. / Benedetti, B.; Rovaris, M.; Rocca, M. A.; Caputo, D.; Zaffaroni, M.; Capra, R.; Bertolotto, A.; Martinelli, V.; Comi, G.; Filippi, Massimo.

In: Multiple Sclerosis Journal, Vol. 15, No. 7, 2009, p. 789-794.

Research output: Contribution to journalArticle

@article{400ba9b29d3741ef8fcd2de0bbf0002e,
title = "In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis",
abstract = "Objective: The term benign multiple sclerosis (BMS) is referred to patients who have a mild or absent disability several years after disease clinical onset. Axonal damage can be measured in vivo using proton MR spectroscopy (1H-MRS). In this study, we quantified the severity of {"}global{"} axonal damage in BMS and early relapsing-remitting (RR) MS patients, using whole brain N-acetylaspartate (WBNAA) 1H-MRS, to better elucidate the structural correlates of a non-disabling disease evolution. Methods: WBNAA concentration was measured in 37 patients with BMS (mean disease duration 22.3 years) and 17 patients with early RRMS (mean disease duration 4.0 years), using an unlocalized 1H-MRS sequence. Dual echo and T1-weighted scans were also obtained to measure T2-hyperintense lesion volume (TLV) and normalized brain volume (NBV). Results: TLV was higher in BMS (mean TLV = 13.1 mL) than in early RRMS patients (mean TLV = 7.2 mL) (P = 0.018), whereas neither NBV (mean NBV: 1491.0 mL in BMS vs 1520.3 mL in RRMS) nor WBNAA concentration (mean WBNAA: 10.5 mmol in BMS vs 11.4 mmol in RRMS) significantly differed between the two groups. In MS patients, no correlation was found between WBNAA concentration and Expanded Disability Status Scale (EDSS), TLV and NBV. Conclusions: The similar WBNAA concentrations seen in BMS and early RRMS patients fit with the notion that a non-disabling long-term evolution of MS may be due, at least in part, to non-progression of pathology. Such a condition seems to be independent from MRI-visible lesions burden.",
keywords = "Axonal damage, Benign, MR spectroscopy, Multiple sclerosis, Relapsing-remitting",
author = "B. Benedetti and M. Rovaris and Rocca, {M. A.} and D. Caputo and M. Zaffaroni and R. Capra and A. Bertolotto and V. Martinelli and G. Comi and Massimo Filippi",
year = "2009",
doi = "10.1177/1352458509103714",
language = "English",
volume = "15",
pages = "789--794",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis

AU - Benedetti, B.

AU - Rovaris, M.

AU - Rocca, M. A.

AU - Caputo, D.

AU - Zaffaroni, M.

AU - Capra, R.

AU - Bertolotto, A.

AU - Martinelli, V.

AU - Comi, G.

AU - Filippi, Massimo

PY - 2009

Y1 - 2009

N2 - Objective: The term benign multiple sclerosis (BMS) is referred to patients who have a mild or absent disability several years after disease clinical onset. Axonal damage can be measured in vivo using proton MR spectroscopy (1H-MRS). In this study, we quantified the severity of "global" axonal damage in BMS and early relapsing-remitting (RR) MS patients, using whole brain N-acetylaspartate (WBNAA) 1H-MRS, to better elucidate the structural correlates of a non-disabling disease evolution. Methods: WBNAA concentration was measured in 37 patients with BMS (mean disease duration 22.3 years) and 17 patients with early RRMS (mean disease duration 4.0 years), using an unlocalized 1H-MRS sequence. Dual echo and T1-weighted scans were also obtained to measure T2-hyperintense lesion volume (TLV) and normalized brain volume (NBV). Results: TLV was higher in BMS (mean TLV = 13.1 mL) than in early RRMS patients (mean TLV = 7.2 mL) (P = 0.018), whereas neither NBV (mean NBV: 1491.0 mL in BMS vs 1520.3 mL in RRMS) nor WBNAA concentration (mean WBNAA: 10.5 mmol in BMS vs 11.4 mmol in RRMS) significantly differed between the two groups. In MS patients, no correlation was found between WBNAA concentration and Expanded Disability Status Scale (EDSS), TLV and NBV. Conclusions: The similar WBNAA concentrations seen in BMS and early RRMS patients fit with the notion that a non-disabling long-term evolution of MS may be due, at least in part, to non-progression of pathology. Such a condition seems to be independent from MRI-visible lesions burden.

AB - Objective: The term benign multiple sclerosis (BMS) is referred to patients who have a mild or absent disability several years after disease clinical onset. Axonal damage can be measured in vivo using proton MR spectroscopy (1H-MRS). In this study, we quantified the severity of "global" axonal damage in BMS and early relapsing-remitting (RR) MS patients, using whole brain N-acetylaspartate (WBNAA) 1H-MRS, to better elucidate the structural correlates of a non-disabling disease evolution. Methods: WBNAA concentration was measured in 37 patients with BMS (mean disease duration 22.3 years) and 17 patients with early RRMS (mean disease duration 4.0 years), using an unlocalized 1H-MRS sequence. Dual echo and T1-weighted scans were also obtained to measure T2-hyperintense lesion volume (TLV) and normalized brain volume (NBV). Results: TLV was higher in BMS (mean TLV = 13.1 mL) than in early RRMS patients (mean TLV = 7.2 mL) (P = 0.018), whereas neither NBV (mean NBV: 1491.0 mL in BMS vs 1520.3 mL in RRMS) nor WBNAA concentration (mean WBNAA: 10.5 mmol in BMS vs 11.4 mmol in RRMS) significantly differed between the two groups. In MS patients, no correlation was found between WBNAA concentration and Expanded Disability Status Scale (EDSS), TLV and NBV. Conclusions: The similar WBNAA concentrations seen in BMS and early RRMS patients fit with the notion that a non-disabling long-term evolution of MS may be due, at least in part, to non-progression of pathology. Such a condition seems to be independent from MRI-visible lesions burden.

KW - Axonal damage

KW - Benign

KW - MR spectroscopy

KW - Multiple sclerosis

KW - Relapsing-remitting

UR - http://www.scopus.com/inward/record.url?scp=67649304790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649304790&partnerID=8YFLogxK

U2 - 10.1177/1352458509103714

DO - 10.1177/1352458509103714

M3 - Article

VL - 15

SP - 789

EP - 794

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 7

ER -